Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00640341 · ClinicalTrials.gov registry record · Phase 4
Comparative Performance of PureVision, Acuvue Oasys and O2Optix
A Phase 4 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 4
- Development phase
- 510
- Enrollment target
NCT00640341 is a Phase 4 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 510 participants.
The verdict
NCT00640341, a Phase 4 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 510 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the performance of the PureVision Contact Lens compared to Acuvue Oasys Contact lens and O2Optix Contact lens when worn on a daily wear basis.
Interventions
- DEVICE PureVision Contact Lens
- DEVICE Acuvue Oasys Contact Lens
- DEVICE O2Optix Contact lens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00640341
The ClinicalTrials.gov registry entry for NCT00640341 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 510 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which PureVision Contact Lens is the first listed.
NCT00640341 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00640341 about?
NCT00640341 is a clinical study titled "Comparative Performance of PureVision, Acuvue Oasys and O2Optix". The objective of this study is to evaluate the performance of the PureVision Contact Lens compared to Acuvue Oasys Contact lens and O2Optix Contact lens when worn on a daily wear basis.
What is the current status of trial NCT00640341?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 510 participants. The study started on 2008-02. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00640341?
The interventions under investigation include: PureVision Contact Lens (DEVICE), Acuvue Oasys Contact Lens (DEVICE), O2Optix Contact lens (DEVICE).
Who is sponsoring clinical trial NCT00640341?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.